Changes of antimicrobial resistance and extended-spectrum β-lactamase production in Klebsiella spp. strains

Timko, Jaroslav

doi:10.1007/s10156-004-0326-2

Cited by 12 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the availability of an adequate antibiotic regimen, the outcome is often fatal, with observed mortality rates around 50%. The high prevalence of multidrugresistant isolates further complicates the treatment of these infections (69). Capsule polysaccharide (CPS) is recognized as one of the most important virulence factors of this pathogen.…”

mentioning

confidence: 99%

Klebsiella pneumoniae Capsule Polysaccharide Impedes the Expression of β-Defensins by Airway Epithelial Cells

et al. 2010

View full text Add to dashboard Cite

mentioning

confidence: 99%

Klebsiella pneumoniae Capsule Polysaccharide Impedes the Expression of β-Defensins by Airway Epithelial Cells

et al. 2010

View full text Add to dashboard Cite

“…isolates in Slovakia. 17 Multidrug resistance is defi ned as resistance to three or more classes of antibiotics. In the present study, the prevalence of MDR K. pneumoniae resistant to ciprofl oxacin, gentamicin, and TMP-SMX was 0.6% and 1.7% in the outpatient and hospital-acquired isolates, respectively (P = 0.045).…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial resistance of Klebsiella pneumoniae in a Saudi Arabian hospital: results of a 6-year surveillance study, 1998–2003

Al‐Tawfiq

Antony

2007

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…The rate of ceftazidime resistance in K. pneumoniae increased from 6% in 1995-1996 [10] to 20% in this study. Multiresistant K. pneumoniae increased worldwide [16][17][18] . There was no apparent change of P. aeruginosa and E. cloacae susceptibilities compared to a previous study [10] .…”

Section: Discussionmentioning

confidence: 99%

Bacteremia in Patients with Hematological Malignancies

Wang

Lin

Liu³

2005

Chemotherapy

View full text Add to dashboard Cite

Background: An appropriate regimen in the empirical therapy of neutropenic fever episodes must be individualized at each institution. Hospitals have different patterns of microbial isolates and antibiotic resistance that must be taken into account. The aim of this study was to investigate isolates of bacteremia and their antibiotic susceptibility in patients with hematological malignancies. Methods: All positive blood cultures at a medical center in Taiwan between 1999 and 2002 from patients with hematological malignancies were evaluated. Eleven kinds of antibiotics were tested for antimicrobial activities. The risk factors for mortality were evaluated. Results: Three hundred seventy-one episodes of bacteremia in 266 patients with hematological malignancies were recorded. Gram-negative bacilli (GNB) were still predominant and accounted for 78.2% of isolates, followed by gram-positive cocci for 20.8% of isolates, and anaerobes for 1% of isolates. Escherichia coli was the most common isolated organism accounting for 27.5% of GNB isolates. Other isolates included Klebsiella pneumoniae (19.3%), Pseudomonas aeruginosa (11%), and Enterobacter cloacae (10.1%). The most isolated microorganisms were susceptible to cefoperazone/sulbactam, piperacillin/tazobactam, cefepime or imipenem. Age, GNB microorganism and inadequate empirical antibiotics were risk factors. Conclusions: We suggest that cefoperazone/sulbactam, piperacillin/tazobactam, cefepime or imipenem is an ideal empirical therapy.

show abstract

Changes of antimicrobial resistance and extended-spectrum β-lactamase production in Klebsiella spp. strains

Cited by 12 publications

References 25 publications

Klebsiella pneumoniae Capsule Polysaccharide Impedes the Expression of β-Defensins by Airway Epithelial Cells

Klebsiella pneumoniae Capsule Polysaccharide Impedes the Expression of β-Defensins by Airway Epithelial Cells

Antimicrobial resistance of Klebsiella pneumoniae in a Saudi Arabian hospital: results of a 6-year surveillance study, 1998–2003

Bacteremia in Patients with Hematological Malignancies

Contact Info

Product

Resources

About